Applies to Medicaid plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Non-preferred GLP-1 for Type 2 Diabetes — Step Through Preferred
All of:
- Diagnosis of Type 2 Diabetes Mellitus
Plus any one of:
- Documented side effect with a preferred GLP-1 product
- Documented allergy to a preferred GLP-1 product
- Documented contraindication to a preferred GLP-1 product
- Treatment failure of a preferred GLP-1 product (defined as <1% reduction in HbA1c after 12 weeks at maximally tolerated dose)
Documentation to bring
- Documentation of Type 2 Diabetes Mellitus diagnosis
- Documentation of side effect, allergy, contraindication, or treatment failure with a preferred GLP-1 product
Quantity limits
- all strengths — 9 mL/84 days (84-day)
Policy note: Ozempic is a non-preferred agent requiring PA. Patient must have documented side effect, allergy, contraindication, or treatment failure with a preferred GLP-1 product. Treatment failure is defined as <1% reduction in HbA1c after 12 weeks at the maximally tolerated dose. Prior glp1_trial duration days set to 84 based on the 12-week treatment failure definition.
Policy effective April 17, 2026 · verified June 4, 2026 · source: Vermont Pdl 20260417 · View policy document (PDF)